CYTOF
Price
$0.10
Change
-$0.00 (-0.00%)
Updated
May 22 closing price
Capitalization
466.21K
ESLA
Price
$0.97
Change
-$0.03 (-3.00%)
Updated
May 23, 01:13 PM (EDT)
Capitalization
36.17M
Interact to see
Advertisement

CYTOF vs ESLA

Header iconCYTOF vs ESLA Comparison
Open Charts CYTOF vs ESLABanner chart's image
Altamira Therapeutics
Price$0.10
Change-$0.00 (-0.00%)
Volume$4.06K
Capitalization466.21K
Estrella Immunopharma
Price$0.97
Change-$0.03 (-3.00%)
Volume$100
Capitalization36.17M
CYTOF vs ESLA Comparison Chart
Loading...
ESLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTOF vs. ESLA commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTOF is a Hold and ESLA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (CYTOF: $0.10 vs. ESLA: $1.00)
Brand notoriety: CYTOF and ESLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTOF: 77% vs. ESLA: 6%
Market capitalization -- CYTOF: $466.21K vs. ESLA: $36.17M
CYTOF [@Biotechnology] is valued at $466.21K. ESLA’s [@Biotechnology] market capitalization is $36.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTOF’s FA Score shows that 1 FA rating(s) are green whileESLA’s FA Score has 0 green FA rating(s).

  • CYTOF’s FA Score: 1 green, 4 red.
  • ESLA’s FA Score: 0 green, 5 red.
According to our system of comparison, CYTOF is a better buy in the long-term than ESLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ESLA’s TA Score shows that 6 TA indicator(s) are bullish.

  • ESLA’s TA Score: 6 bullish, 4 bearish.

Price Growth

CYTOF (@Biotechnology) experienced а 0.00% price change this week, while ESLA (@Biotechnology) price change was +6.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.72%. For the same industry, the average monthly price growth was +2.76%, and the average quarterly price growth was -2.87%.

Reported Earning Dates

CYTOF is expected to report earnings on Apr 30, 2025.

ESLA is expected to report earnings on May 14, 2025.

Industries' Descriptions

@Biotechnology (+0.72% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ESLA($36.2M) has a higher market cap than CYTOF($466K). CYTOF YTD gains are higher at: -9.502 vs. ESLA (-16.667).
CYTOFESLACYTOF / ESLA
Capitalization466K36.2M1%
EBITDAN/A-8.82M-
Gain YTD-9.502-16.66757%
P/E Ratio0.05N/A-
RevenueN/A0-
Total CashN/A1.8M-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
CYTOF: Fundamental Ratings
CYTOF
OUTLOOK RATING
1..100
21
VALUATION
overvalued / fair valued / undervalued
1..100
8
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
61
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ESLA
RSI
ODDS (%)
Bearish Trend 2 days ago
36%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
54%
Momentum
ODDS (%)
Bearish Trend 2 days ago
55%
MACD
ODDS (%)
Bearish Trend 2 days ago
44%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
40%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
37%
Advances
ODDS (%)
Bullish Trend 5 days ago
76%
Declines
ODDS (%)
Bearish Trend 9 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bullish Trend 2 days ago
32%
View a ticker or compare two or three
Interact to see
Advertisement
ESLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FAST81.4640.73
+100.00%
Fastenal Co
ONTF5.36N/A
N/A
ON24
ACT35.33-0.36
-1.01%
Enact Holdings
JKS18.47-0.31
-1.65%
Jinkosolar Holdings CO
NRSN1.46-0.04
-2.67%
NeuroSense Therapeutics Ltd

CYTOF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTOF has been loosely correlated with CMND. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTOF jumps, then CMND could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTOF
1D Price
Change %
CYTOF100%
+0.55%
CMND - CYTOF
56%
Loosely correlated
N/A
COGT - CYTOF
40%
Loosely correlated
N/A
SPHDF - CYTOF
35%
Loosely correlated
N/A
LOGC - CYTOF
32%
Poorly correlated
-3.98%
UBX - CYTOF
29%
Poorly correlated
+4.48%
More

ESLA and

Correlation & Price change

A.I.dvisor tells us that ESLA and CARM have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESLA and CARM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESLA
1D Price
Change %
ESLA100%
-0.99%
CARM - ESLA
26%
Poorly correlated
+4.78%
IMUX - ESLA
25%
Poorly correlated
+0.08%
IONS - ESLA
25%
Poorly correlated
N/A
WINT - ESLA
24%
Poorly correlated
-5.00%
CYTOF - ESLA
23%
Poorly correlated
+0.55%
More